+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Mild Cognitive Impairment - Pipeline Review, H1 2017

  • ID: 4200777
  • Report
  • April 2017
  • 124 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AgeneBio Inc
  • Eisai Co Ltd
  • Ensol Biosciences Inc
  • IntelGenx Corp
  • Nanotherapeutics Inc
  • NLS Pharma Group
  • MORE
Mild Cognitive Impairment - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2017, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 7, 1, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • AgeneBio Inc
  • Eisai Co Ltd
  • Ensol Biosciences Inc
  • IntelGenx Corp
  • Nanotherapeutics Inc
  • NLS Pharma Group
  • MORE
Introduction

Report Coverage

Mild Cognitive Impairment - Overview

Mild Cognitive Impairment - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mild Cognitive Impairment - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mild Cognitive Impairment - Companies Involved in Therapeutics Development

AgeneBio Inc

Avraham Pharmaceuticals Ltd

CereSpir Inc

ConSynance Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Company

Ensol Biosciences Inc

Genzyme Corp

IntelGenx Corp

Krenitsky Pharmaceuticals Inc

Merck & Co Inc

Nanotherapeutics Inc

Neuron Biopharma SA

NLS Pharma Group

Octapharma AG

Pfizer Inc

Sage Therapeutics Inc

SBI Pharmaceuticals Co Ltd

Suven Life Sciences Ltd

Takeda Pharmaceutical Company Ltd

Therapix Biosciences Ltd

Mild Cognitive Impairment - Drug Profiles

aminolevulinic acid hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAN-2401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bosutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexanolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSP-1103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSTI-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DAOI-B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elenbecestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-544 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ladostigil tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levetiracetam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levofacetoperane - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3002813 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3303560 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

montelukast sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Moriah-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPS-0158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPS-0163 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NST-0037 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NST-0076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NST-0078 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTC-942 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-507 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-512 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVNI-1307014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-071 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tropisetron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verubecestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEN-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mild Cognitive Impairment - Dormant Projects

Mild Cognitive Impairment - Discontinued Products

Mild Cognitive Impairment - Product Development Milestones

Featured News & Press Releases

Oct 31, 2016: Therapix Biosciences Successfully Completed the Development of a Formulation for a Tablet for Sublingual Administration of THC for Pharmaceutical Use

Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain

Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast

Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment

Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI

Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON

May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment

Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m

Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer’s Disease At ICAD 2009, Vienna, Austria.

Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland

Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London

Sep 29, 2008: Suven Completes Phase-I Clinical Trials Single Ascending Dose Of Suvn-502 In Switzerland

Sep 25, 2008: Suven Life Sciences Ltd. Announces DCGI Nod To Conduct Phase-I Clinical Trials Of Suvn-502 For Alzheimer’S Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Mild Cognitive Impairment, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H1 2017

Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H1 2017

Mild Cognitive Impairment - Pipeline by CereSpir Inc, H1 2017

Mild Cognitive Impairment - Pipeline by ConSynance Therapeutics Inc, H1 2017

Mild Cognitive Impairment - Pipeline by Eisai Co Ltd, H1 2017

Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H1 2017

Mild Cognitive Impairment - Pipeline by Ensol Biosciences Inc, H1 2017

Mild Cognitive Impairment - Pipeline by Genzyme Corp, H1 2017

Mild Cognitive Impairment - Pipeline by IntelGenx Corp, H1 2017

Mild Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017

Mild Cognitive Impairment - Pipeline by Merck & Co Inc, H1 2017

Mild Cognitive Impairment - Pipeline by Nanotherapeutics Inc, H1 2017

Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H1 2017

Mild Cognitive Impairment - Pipeline by NLS Pharma Group, H1 2017

Mild Cognitive Impairment - Pipeline by Octapharma AG, H1 2017

Mild Cognitive Impairment - Pipeline by Pfizer Inc, H1 2017

Mild Cognitive Impairment - Pipeline by Sage Therapeutics Inc, H1 2017

Mild Cognitive Impairment - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017

Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd, H1 2017

Mild Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H1 2017

Mild Cognitive Impairment - Dormant Projects, H1 2017

Mild Cognitive Impairment - Dormant Projects, H1 2017 (Contd..1), H1 2017

Mild Cognitive Impairment - Discontinued Products, H1 2017

List of Figures:

Number of Products under Development for Mild Cognitive Impairment, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
4 of 5
  • AgeneBio Inc
  • Avraham Pharmaceuticals Ltd
  • CereSpir Inc
  • ConSynance Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Ensol Biosciences Inc
  • Genzyme Corp
  • IntelGenx Corp
  • Krenitsky Pharmaceuticals Inc
  • Merck & Co Inc
  • Nanotherapeutics Inc
  • Neuron Biopharma SA
  • NLS Pharma Group
  • Octapharma AG
  • Pfizer Inc
  • Sage Therapeutics Inc
  • SBI Pharmaceuticals Co Ltd
  • Suven Life Sciences Ltd
  • Takeda Pharmaceutical Company Ltd
  • Therapix Biosciences Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll